Browse Articles

In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.

Since cancer cells inhibit T-cell activity, the authors investigated a method to reverse T-cell disfunction with gene therapy, so that the T-cells would become effective once again in fighting cancer cells. They used the inhibition of proprotein convertases (PCSK1) in T cells and programmed death-ligand 1 (CD274) in cancer cells. They observed the recovery of IL-2 expression in Jurkat cells, with increased recovery noted in a co-culture sample. This study suggests a novel strategy to reactivate T cells.

Tertiary lymphoid structures (TLS) are lymph node-like structures that form at sites of inflammation, and their presence in cancer patients is predictive of a better clinical outcome. One significant obstacle to TLS formation is reduced immune cell infiltration into the tumor microenvironment (TME). Recent studies have shown that vasculature normalizing (VN) agents may override this defect to improve tissue perfusion and increased immune cell entry into the TME. However, their effects on immune cell and tumor cell phenotype remain understudied. Here the authors investigate whether treating tumor cells with VN would reduce their immunosuppressive phenotype and promote production of chemokine that recruit immune cells and foster TLS formation.

Minimal Change Disease (MCD) is a degenerative kidney disease. Researchers know very little about the cause of this disorder, however some research has suggested that T lymphocytes may be involved. In this study, the authors measure CD4 and CD8 T cell subpopulations in patients with MCD to investigate whether irregular T lymphocyte populations may be involved in MCD pathogenesis.

In this study, the authors investigated the time-dependent cytokine secretion ability of phyto-hemagglutinin (PHA)-activated T cells derived from human peripheral (PB) and cord blood (CB). They hypothesized that the anti-inflammatory cytokine, IL-10, and pro-inflammatory cytokine, TNFα, levels would be higher in PHA-activated T cells obtained from PB as compared to the levels obtained from CB and would decrease over time. Upon PHA-activation, the IL-10 levels were relatively high while the TNFα levels decreased, making these findings applicable in therapeutic treatments e.g., rheumatoid arthritis, psoriasis, and organ transplantation.

Here, seeking to better understand the roles of glycans in the receptors of active sites of neuronal cells, the authors used molecular dynamics simulations to to uncover the dynamic nature of N-glycans on membrane proteins. The authors suggest the study of theinteractions of these membrane poreins could provide future potential therapeutic targets to treat mental diseases.

In this study, the authors identify new potential targets to treat advanced diffuse large B-cell lymphoma after treatment relapse and loss of CD19 expression.

T. pyriformis can use phagocytosis to create vacuoles of carmine red, a dye which is made using crushed insects and is full of nutrients. Establishing a relationship between vacuole formation and duration of exposure to food can demonstrate how phagocytosis occurs in T. pyriformis. We hypothesized that if T. pyriformis was incubated in a carmine red solution, then more vacuoles would form over time in each cell.

Gamma radiation can be produced by both natural and man-made sources and abnormally high exposure levels could lead to an increase in cell damage. In this study, gamma radiation was measured at different locations and any correlation with various geographic factors, such as distance from a city center, elevation and proximity to the nearest nuclear reactor, was determined.

The authors investigate whether human blood cancers carrying mutations in DNA repair genes possess increased sensitivity to common chemotherapy drugs cisplatin or gemcitabine.